Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a generally positive outlook: Stoke Therapeutics has a “Moderate Buy” consensus from 11 analysts, with 10 buy ratings and one sell rating. The average 12-month price target is $44.25 versus the reported share price of $31.62.
• Quarterly results missed expectations: The company reported an adjusted loss of $0.93 per share, below the $0.80 consensus estimate, while revenue of $9.32 million exceeded expectations. Analysts forecast a full-year loss of $3.52 per share.
• Insiders have been selling shares: Company insiders sold 30,623 shares worth approximately $953,765 over the past 90 days, though some sales were conducted under a trading plan or to cover tax obligations. Several institutional investors, including Bank of America and Dimensional Fund Advisors, increased their positions.

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $44.25.

STOK has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. Canaccord Genuity Group reduced their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating on the stock in a research note on Tuesday, August 4th. Chardan Capital restated a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. BTIG Research restated a "buy" rating and set a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. initiated coverage on Stoke Therapeutics in a research report on Friday, August 21st. They set an "overweight" rating and a $40.00 target price for the company.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 7,176 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $29.04, for a total value of $208,391.04. Following the transaction, the insider owned 20,422 shares of the company's stock, valued at $593,054.88. The trade was a 26.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Edward M. Md Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the transaction, the director directly owned 124,557 shares in the company, valued at $3,989,560.71. This represents a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 30,623 shares of company stock valued at $953,765. 9.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds have recently made changes to their positions in the company. Hussman Strategic Advisors Inc. purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $2,000,000. Dimensional Fund Advisors LP raised its stake in shares of Stoke Therapeutics by 19.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 989,936 shares of the company's stock worth $32,229,000 after buying an additional 162,797 shares during the period. Janus Henderson Group PLC raised its position in Stoke Therapeutics by 11.2% during the first quarter. Janus Henderson Group PLC now owns 1,612,781 shares of the company's stock worth $52,456,000 after acquiring an additional 161,848 shares during the period. Candriam S.C.A. raised its position in shares of Stoke Therapeutics by 12.4% during the 1st quarter. Candriam S.C.A. now owns 502,020 shares of the company's stock worth $16,346,000 after purchasing an additional 55,330 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Stoke Therapeutics by 163.4% during the first quarter. Bank of America Corp DE now owns 543,095 shares of the company's stock worth $17,683,000 after purchasing an additional 336,931 shares in the last quarter.

Stoke Therapeutics Stock Performance

NASDAQ STOK opened at $31.62 on Friday. Stoke Therapeutics has a fifty-two week low of $18.80 and a fifty-two week high of $40.22. The company has a market capitalization of $2.04 billion, a PE ratio of -9.47 and a beta of 1.20. The business's fifty day moving average is $31.22 and its 200 day moving average is $32.26.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.13). The company had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. On average, sell-side analysts forecast that Stoke Therapeutics will post -3.52 EPS for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source